Incidence and risk factors of loss to follow-up among HIV-infected children in an antiretroviral treatment program

PLoS One. 2019 Sep 17;14(9):e0222082. doi: 10.1371/journal.pone.0222082. eCollection 2019.

Abstract

Introduction: The success of antiretroviral treatment (ART) programs can be compromised by high rates of patient loss to follow-up (LTFU). We assessed the incidence and risk factors of LTFU in a large cohort of HIV-infected children receiving ART in Thailand.

Methods: All children participating in a multicenter cohort (NCT00433030) between 1999 and 2014 were included. The date of LTFU was 9 months after the last contact date. ART interruption was defined as ART discontinuation for more than 7 days followed by resumption of treatment. Baseline and time-dependent risk factors associated with LTFU were identified using Fine and Gray competing risk regression models with death or referral to another hospital as competing events.

Results: Of 873 children who were followed during a median of 8.6 years (interquartile range 4.5-10.6), 196 were LTFU, 73 died, and 195 referred. The cumulative incidence of LTFU was 2.9% at 1 year, 7.3% at 5 years and 22.2% at 10 years. Children aged 13 years and more had a 3-fold higher risk (95% confidence interval 2.06-4.78) of LTFU than those younger. Children who had interrupted ART within the previous year had a 2.5-fold higher risk (1.12-5.91) than those who had not. The risk of LTFU was lower in children stunted (height-for-age Z-scores <-2 SD) (0.42-0.96) or underweight (weight-for-age Z-scores <-2 SD) (0.24-0.97).

Conclusion: Adolescence, ART interruption and absence of growth deficit were associated with LTFU. These may be warnings that should draw clinicians' attention and possibly trigger specific interventions. Children with no significant growth retardation may also be at risk of LTFU.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-HIV Agents / therapeutic use*
  • Body Height
  • Body Weight
  • Child
  • Child, Preschool
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • HIV Infections / pathology
  • Humans
  • Incidence
  • Infant
  • Lost to Follow-Up
  • Male
  • Prospective Studies
  • Risk Factors
  • Thailand / epidemiology
  • Time Factors

Substances

  • Anti-HIV Agents

Associated data

  • ClinicalTrials.gov/NCT00433030

Grants and funding

The PHPT prospective multicenter cohort study was funded by the Global Fund to AIDS, Tuberculosis and Malaria, Thailand (PR-A-N-008) to ML; Oxfam Great Britain, Thailand (THAA51) to ML; Ministry of Public Health, Thailand; and Institut de Recherche pour le Développement (IRD), France to GJ. This study was financially supported for publication by Chiang Mai University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.